Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system

Discov Med
October 2014
https://www.discoverymedicine.com/Brian-Johnson-2/2014/10/fibromyalgia-autism-and-opioid-addiction-as-natural-and-induced-disorders-of-the-endogenous-opioid-hormonal-system/

Endogenous opioid systems regulate cell proliferation in the developing rat brain

Brain Res
26 May 1987
https://pubmed.ncbi.nlm.nih.gov/3607463/

Opioid antagonist-induced regulation of organ development

Physiol Behav
April 1985
https://pubmed.ncbi.nlm.nih.gov/4011730/

Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth

Life Sci
12 November 1984
https://pubmed.ncbi.nlm.nih.gov/6092812/

Naltrexone modulates growth in infant rats

Life Sci
12 December 1983
https://pubmed.ncbi.nlm.nih.gov/6316064/

Featured Article: Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Exp Biol Med (Maywood)
September 2017
https://pubmed.ncbi.nlm.nih.gov/28766982/

The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet]

Report from Norwegian Knowledge Centre for the Health Services
April 2015
https://pubmed.ncbi.nlm.nih.gov/28510411/

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis

Exp Biol Med (Maywood)
February 2018
https://pubmed.ncbi.nlm.nih.gov/29307283/

McLaughlin leads research on identifying minimally invasive biomarkers for MS

Penn State News
10 April 2018
https://news.psu.edu/story/515260/2018/04/10/research/mclaughlin-leads-research-identifying-minimally-invasive-biomarkers

Low-dose Naltrexone Changes Levels of Inflammatory Proteins in MS, Study Shows

MS News Today
20 February 2018
https://multiplesclerosisnewstoday.com/2018/02/20/low-dose-naltrexone-changes-levels-inflammatory-proteins-in-ms/